retatrutide ly3437943 triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide

A vendor selling 98% purity retatrutide who provides an HPLC chromatogram, mass spectrometry data, and batch-specific testing results is operating at a fundamentally different level than one who simply prints "98% purity" on a label

Retatrutide is currently an investigational medication undergoing clinical trials, and regulatory approval status may vary by country

Staying well-hydrated helps your body digest food more easily and move it more swiftly through your digestive tract

Weight management issues are common in women dealing with conditions like menopause, PCOS or endometriosis

To date, there are no full-length research articles describing changes in RA disease activity following treatment with GLP-1 receptor agonists, he says

Concerns about delayed treatment Dr